Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2001

01-04-2001 | Leading Article

Emerging Strategies in Infectious Diseases

New Carbapenem and Trinem Antibacterial Agents

Authors: Dr Hélio S. Sader, Ana C. Gales

Published in: Drugs | Issue 5/2001

Login to get access

Abstract

β-Lactam antibiotics represent the most commonly prescribed antibacterial agents. New β-lactams have been introduced continuously as many bacteria have developed resistance to older agents. In the late 1970s, a new class of exceptionally broad spectrum β-lactams, the carbapenems, was identified. Despite being a very potent compound, the antibacterial activity of the first carbapenem, imipenem, was compromised because of hydrolysis by the renal dehydropeptidase enzyme (DHP-1), and it is now coadministered with a potent competitive inhibitor of the DHP-1 enzyme, cilastin. Molecular modifications in the carbapenem nucleus were able to increase stability to DHP-1 and retain the antibacterial activity. However, some important pathogenic bacteria were found to be resistant to this new class of agents. In addition, other clinically important Gram-negative species, such as Pseudomonas aeruginosa, developed resistance mainly by the production of potent β-lactamases and reduced permeability of the outer membrane. Since the discovery of imipenem/cilastatin, a great number of carbapenems have been developed, and a few of them have been marketed. Stability to hydrolysis by DHP-1 and decrease in toxicity were achieved by meropenem and biapenem. However, only a slight increase in the antibacterial potency and spectrum has been accomplished with either the new marketed or experimental parenteral compounds. In addition, compounds that can be administered orally, such as the carbapenens faropenem, CS-834 and MK-826, and the trinem sanfetrinem, have been developed. However, when compared with the parenterally administered compounds, the oral agents seem to lose some in vitro antibacterial activity, especially against P. aeruginosa.
Literature
1.
Livermore DM, Williams DJ. β-lactams: mode of action and mechanism of bacterial resistance. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1996: 502–78
2.
Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimcrobial agents. N Engl J Med 1991; 324: 601–12PubMedCrossRef
3.
Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33PubMedCrossRef
4.
Philippon A, Labia R, Jacoby GA. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131–6PubMedCrossRef
5.
Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998 Jul; 31: 461–6PubMedCrossRef
6.
Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. Antimicrob Agents Chemother 1983; 12D Suppl.: 1S–35S
7.
Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30: 129–34PubMedCrossRef
8.
Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994 Mar; 38: 547–57PubMedCrossRef
9.
Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11: 93–100PubMedCrossRef
10.
Coulton S, Hunt E. Recent Advances in the chemistry and biology of carbapenems antibiotics. In: Ellis GP, Lumskobe DK, editors. Progress in medicinal chemistry. Amsterdam, Elsevier Science BV, 1996: 99–145
11.
Andrus A, Baker FA, Bouffard FA, et al. Structure-activity relationships among some totally synthetic carbapenems. In: Brown AG, Roberts SM, editors. Recent advances in the chemistry of β-lactams. London: The Royal Society of Chemistry, 1984: 86–99
12.
Christensen BG. Structure activity relationships in beta-lactam antibiotics. In: Salton MEJ, Schockman GD, editors. Betalactam antibiotics. Mode of action, new development, and future prospects. London: Academic Press, 1981: 101–25
13.
Miyadera T, Sugimura Y, Hashimoto T, et al. Synthesis and in vitro activity of a new carbapenem, RS-533. J Antibiot 1983 Aug; 36: 1034–9PubMedCrossRef
14.
Edwards JR, Betts MJ. Carbapenems: the pinnacle of the β-lactam antibiotics or room for improvement. J Antimicrob Chemother 2000 Jan; 45: 1–4PubMedCrossRef
15.
Tanimura H, Ochiai M, Sugimoto Y, et al. Tissue concentration and clinical efficacy of panipenem/betamipron in surgical infections. Chemotherapy Tokyo 1991; 39: 585–95
16.
Edwards JR, Turner PJ, Wannop C, et al. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase. I. Antimicrob Agents Chemother 1989 Feb; 33: 215–22CrossRef
17.
Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase. I. Antimicrob Agents Chemother 1990 June; 34: 994–1000CrossRef
18.
Petersen PJ, Jacobous NV, Weiss WJ, et al. In vitro and in vivo activity of LJC10,627, a new carbapenem antibiotic with stability to dehydropeptidase. I. Antimicrob Agents Chemother 1991 Jan; 35: 203–7CrossRef
19.
Neu HC, Gu JW, Fang W, et al. In vitro activity and β-lactamase stability of LJC 10, 627. Antimicrob Agents Chemother 1992 Jul; 36: 1418–23PubMedCrossRef
20.
Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 1993 Sep; 37: 2009–16PubMedCrossRef
21.
Clarke AM, Zemcov SJV. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993; 12: 377–84PubMedCrossRef
22.
Catchopole CR, Wise R, Thornber D, et al. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992 Sep; 36: 1928–34CrossRef
23.
Sader HS, Jones RN. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem, and other broad-spectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993; 12: 384–91PubMedCrossRef
24.
Nord CE, Lahnborg G. Biapenem versus imipenem in the treatment of experimental intra-abdominal infections. J Chemother 1995 Feb; 7: 42–4PubMed
25.
Hikida M, Masukawa Y, Nishiki K, et al. Low neurotoxicity of LJC 10,627, a novel 1β-methyl carbapenem antibiotic: inhibition of γ-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993 Feb; 37: 199–202PubMedCrossRef
26.
Hikida M, Kawashima K, Nishiki K, et al. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992 Feb; 36: 481–3PubMedCrossRef
27.
Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998 Jun; 42: 1433–6PubMed
28.
Toynaga Y, Ishihara T, Tezuka T, et al. Pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field [in Japanese]. Jpn J Antibiot 1994 Dec; 47: 1691–705PubMed
29.
Brismar Bo, Åkerlund JE, Sjöstedt S, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Scand J Infect Dis 1996; 28: 507–12PubMedCrossRef
30.
Ohtake N, Okamoto O, Mitomo R, et al. lβ-methyl-2-(5-sustituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and antibacterial activity of BO-2727 and its related compounds. J Antibiot 1997 Jul; 50: 598–613
31.
Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother 1996; 37: 1034–6PubMedCrossRef
32.
Hashizume T, Nakamura K, Nakagawa S. Affinities of BO-2727 for bactericidal penicillin-binding proteins and morphological change of Gram-negative rods. J Antibiot 1997 Feb; 50: 139–42PubMedCrossRef
33.
Kato Y, Otsuki M, Nishino T. Antibacterial properties of BO-2727, a new carbapenem antibiotic. J Antimicrob Chemother 1997; 40: 195–203PubMedCrossRef
34.
Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiot 1997 Feb; 50: 135–8PubMedCrossRef
35.
Mikamo H, Kawazoe K, Izumi K, et al. In vitro and in vivo antibacterial of a new carbapenem BO-2727 for use in obstetrics and gynecology. Chemother 1998; 44: 12–6CrossRef
36.
Miyauchi M, Endo R, Hisaoka M, et al. Synthesis and structure-activity relantionships of a novel oral carbapenem, CS-834. J Antibiot 1997 May; 50: 429–39PubMedCrossRef
37.
Miyauchi M, Kanno M, Kawamoto I. A novel oral carbapenem CS-834: chemical stability of pivaloyloxymethyl esters of carbapenems and cephalosporins in phosphate buffer solution. J Antibiot 1997 Sep; 50: 794–5PubMedCrossRef
38.
Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivamecillinam therapy. Lancet 1989 Aug; 2: 469–73PubMedCrossRef
39.
Umemura K, Ikeda Y, Kondo K, et al. Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1997 Dec; 41: 2664–9PubMed
40.
Sakagawa E, Otsuki M, Ou T, et al. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem. J Antimicrob Chemother 1998; 42: 427–37PubMedCrossRef
41.
Fukuoka T, Ohya S, Utsui Y, et al. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother 1997 Dec; 41: 2652–63PubMed
42.
Yamaguchi K, Domon H, Miyazaki S, et al. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob Agents Chemother 1998 Mar; 42: 555–63PubMedCrossRef
43.
Fukuoka T, Kawada H, Kitayama A, et al. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob Agents Chemother 1998 Jan; 42: 23–7PubMed
44.
Gill CJ, Jackson JJ, Gerckens LS, et al. In vitro activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749, 345). Antimicrob Agents Chemother 1998 Aug; 42: 1996–2001PubMed
45.
Fuchs PC, Barry AL, Brown SD. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and a provisional interpretative criteria for disc tests. J Antimicrob Chemother 1999; 43: 703–6PubMedCrossRef
46.
Odenholt I, Löwdin E, Cars O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 1998 Sep; 42: 2365–70PubMed
47.
Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens. Antimicrob Agents Chemother 1997 Aug; 41: 1830–1PubMed
48.
Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999 May; 43: 1170–6PubMed
49.
Sundelof JG, Hajdu R, Gill CJ, et al. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother 1997 Aug; 41: 1743–8PubMed
50.
Majumdar A, Birk K, Blum RA, et al. Pharmacokinetics of L-749,345, a carbapenem antibiotic, in healthy male and female volunteers [abstract F130]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1996: 122
51.
Sturm A, Pachon-Diaz J, Bach M, et al. Phase IIA randomized, double-blind, multicenter study of MK-826 versus ceftriaxone sodium in the treatment of serious lower respiratory tract infections: a preliminary analysis [abstract]. Clin Infect Dis 1998 Oct; 27: 952
52.
Kim SH, Kim WB, Lee MG. Stability, tissue metabolism, tissue distribution, and blood partition of DA-1131, a new carbapenem. Res Commun Mol Pathol Pharmacol Dec 1995; 90: 347–62
53.
Kim SH, Kwon JW, Lee MG. Pharmacokinetics and tissue distribution of a new carbapenem, DA-1131, after intravenous administration to mice, rats, rabbits, and dogs. Biopharm Drug Dispos 1998; 19: 219–29PubMedCrossRef
54.
Kim SH, Kim WB, Lee MG. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. Antimicrob Agents Chemother 1999 Jan; 43: 96–9PubMed
55.
Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits, and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 1998; 19: 231–5PubMedCrossRef
56.
Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenm. Antimicrob Agents Chemother 1998 Jan; 42: 94–9PubMed
57.
Tanaka M, Hohmura M, Nishi T, et al. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob Agents Chemother 1997 Jun; 41: 1260–8PubMed
58.
Ohba F, Nakamura-Kamijo M, Watanabe N, et al. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother 1997 Feb; 41: 298–307PubMed
59.
Kohler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999 Feb; 43: 424–7PubMed
60.
Yang Y, Testa RT, Bhachech N, et al. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother. 1999 Dec; 43: 2904–9PubMed
61.
Weiss WJ, Mikels SM, Petersen PJ, et al. In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems. Antimicrob Agents Chemother 1999 Mar; 43: 460–4PubMed
62.
Matsumara N, Minami S, Mitsuhashi S. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to β-lactamase. J Antimicrob Chemother 1997; 39: 31–4CrossRef
63.
Modugno ED, Erbetti I, Ferrari L, et al. In vitro activity of the tribactam GV129606 against Gram-positive, Gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother 1994 Oct; 38: 2362–8PubMedCrossRef
64.
Johnson AP, Warner M, Speller DC. In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus. J Antimicrob Chemother 1998 Nov; 42: 643–6PubMedCrossRef
65.
Sifaoui F, Varon E, Kitzis MD, et al. In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998 Jan; 42: 173–5PubMed
66.
Modugno ED, Broggio R, Erbetti I, et al. In vitro and in vivo antibacterial activities of GV 129606, a new broad-spectrum trinem. Antimicrob Agents Chemother 1997 Dec; 41: 2742–8PubMed
67.
Wise R, Andrews JM, Brenwald N. In vitro activity of the tricyclic β-lactam GV 104326. Antimicrob Agents Chemother 1996 May; 40: 1248–53PubMed
68.
Singh KV, Coque TM, Murray BE. In vitro activity of the trinem sanfetrinem (GV 104326) against gram-positive organisms. Antimicrob Agents Chemother 1996 Sep; 40: 2142–6PubMed
69.
Doern GV, Pierce G, Brueggemann AB. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996 Sep; 26: 39–42PubMedCrossRef
70.
Andrews JM, Hadley N, Brenwald NP, et al. Susceptibility testing of fastidious organisms. J Antimicrob Chemother 1997 Mar; 39: 436–7PubMedCrossRef
71.
Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1997 Oct; 41: 2173–6PubMed
72.
Spangler SK, Jacobs MR, Appelbaum PC. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother 1997 Jan; 41: 148–55PubMed
73.
Betriu C, Gomez M, Palau ML, et al. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother 1999 Sep; 43: 2320–2PubMed
74.
Babini GS, Yuan M, Livermore DM. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams. Antimicrob Agents Chemother 1998 May; 42: 1168–75PubMed
75.
Chen HY, Livermore DM. Comparative activity of cefepime against chromosomal β-lactamase inducibility mutants of gram-negative bacteria. J Antimicrob Chemother 1993; 32 Suppl. B: 63–74PubMedCrossRef
76.
Tullio V, Palarchio AI, Bonino A, et al. Sub-MICs of sanfetrinem promote the interaction of human polymorphonuclear granulocytes with a multiply resistant strain of Klebsiella pneumoniae. J Antimicrob Chemother 1998 Aug; 42: 249–52PubMedCrossRef
77.
Cuffini AM, Tullio V, Bonino A, et al. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1998 Jul; 42: 1745–50PubMed
78.
Tamura S, Miyazaki S, Tateda K, et al. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic. Antimicrob Agents Chemother 1998 Jul; 42: 1858–61PubMed
79.
Efthymiopoulos CA, Capriati A, Barrington P, et al. Pharmacokinetics of GV 104326, a novel tribactam antibiotic, following single intravenous and oral (as its prodrug GV118819X) administration in man [abstract F82]. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washinton, DC: American Society for Microbiology, 1994: 129
80.
Wise R, Andrews JM, Da Ros L, et al. A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326). Antimicrob Agents Chemother 1997 Aug; 41: 1761–4PubMed
81.
Sader HS, Pfaller MA, Tenover FC, et al. Evaluation and characterization of multiresistant Enterococcus faecium from twelve U.S. medical centers. J Clin Microbiol 1994 Nov; 32: 2840–2PubMed
82.
Jones RN, Pfaller MA. Bacterial resistance: a worldwide problem. Diagn Microbiol Infect Dis 1998 Jun; 31: 379–88PubMedCrossRef
83.
Sader HS, Mendes CF, Pignatari AC, et al. Use of macrorestriction analysis to demonstration interhospital spread of multi-resistant Acinetobacter baumannii in São Paulo, Brazil. Clin Infect Dis 1996 Sep; 23: 631–4PubMedCrossRef
84.
Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility of patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: results from the SENTRY Antimicrobial Surveillance Program (1997). Diagn Microbiol Infect Dis 1998 Dec; 32: 289–301PubMedCrossRef
85.
Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999 Jun; 43: 1379–82PubMed
Metadata
Title
Emerging Strategies in Infectious Diseases
New Carbapenem and Trinem Antibacterial Agents
Authors
Dr Hélio S. Sader
Ana C. Gales
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161050-00001

Other articles of this Issue 5/2001

Drugs 5/2001 Go to the issue

Review Article

Current Concepts on Pathophysiology, Diagnosis and Treatment of Diffuse Oesophageal Spasm

Adis New Drug Profile

Levosimendan

Therapy in Practice

Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia

Adis New Drug Profile

Bendamustine

Review Article

Topical Corticosteroids in Nasal Polyposis

Adis Drug Evaluation

Amifostine